In a sector governed by safety, precision and stringent regulation, the pharmaceutical industry has long made suitability the cornerstone of packaging design – especially for temperature sensitive products. But in the face of escalating environmental concerns and consumer expectations, the question is evolving: can we maintain reliability without sacrificing sustainability?
As more stakeholders examine the environmental cost of pharmaceutical packaging, a new debate emerges – suitability vs sustainability – and it’s forcing the industry to confront some uncomfortable assumptions.
The legacy of risk aversion
For decades, the pharmaceutical cold chain has operated under a zero-failure mentality: ensure temperature control at all costs. But this defensive posture has led to systems that are over-engineered, single-use and environmentally damaging.
Matthew Rogerson, founder of The Pack Scout and an expert on sustainable packaging, acknowledges the roots of this mindset: “Pharma has always put patient safety and regulatory compliance above every other factor – and rightly so.
“Packaging is judged first on its ability to maintain label conditions, protect integrity and meet GDP/USP <1079> requirements. The industry’s operational DNA has been shaped by decades of risk-averse decision-making: proven materials, validated shippers and lane data take precedence over any untested alternative,” Rogerson explains.
Another factor that has played a decisive role is cost, Rogerson adds: “Procurement teams are tasked with controlling spend, so even where sustainable options exist, they’re often judged on unit price rather than total cost of ownership. And sustainability? For most of the past two decades, it has been an add-on – considered only if it doesn’t compromise the other two priorities.”
This mindset creates a powerful inertia. Once a packaging format is validated, entire networks are built around it – qualification records, supplier contracts and risk management plans. Changing any single component can ripple through multiple departments, making decision-makers cautious. The irony is that while this conservatism protects against risk, it can also delay the adoption of innovations that would lower cost and improve environmental performance in the long run.
In the pharmaceutical industry, overengineering is a virtue. Historically, packaging design has prioritised stability above all else – ensuring products arrive unspoiled, regardless of environmental conditions or transport hiccups. In temperature-sensitive shipments, that often means bulky polystyrene boxes, multi-layer plastic insulation and generous helpings of gel packs or dry ice.
And yet, this ultra-conservative approach has created a mountain of waste. According to Rogerson, the rise of direct-to-consumer pharma and health tech start-ups has only accelerated the problem. “A huge barrier is what I call copy-paste compliance,” he says. “Regulations are often lifted wholesale from one market to another without the matching infrastructure to meet them. The result? On paper, a shipper must be ‘100% recyclable’, but in reality, the receiving market has no facility to process its insulation or PCMs.”
The environmental consequences are now stark: globally, packaging accounts for around 30% of municipal solid waste, and only 10% is recycled into new products. Insulated shipping containers are mostly single-use and – according to life-cycle studies – produce up to 95% more packing waste than reusable alternatives.
Rethinking the end game
It’s easy to frame the discussion as a tug-of-war between performance and planet. After all, pharmaceutical products can’t tolerate failure. The stakes are simply too high. But experts are pushing back on the idea that sustainability and suitability are fundamentally opposed.
But the real issue isn’t necessarily the lack of technology, but more the consumer mindset of the pharmaceutical industry. The industry isn’t lacking in materials or design, and we have the data to know the extent of the issue at hand, yet there still remains a fear of regulation and an emphasis on risk aversion.
“In theory, GDP and USP standards are technologyneutral, but in practice, the path to approval is anything but,” Rogerson explains. “Any change to a thermal shipper must be backed by validation evidence – lane simulations, stability data, OQ/PQ records – proving it is equal or superior to the incumbent system. That’s expensive and time-sensitive.”
The good news? Innovation is closing the gap. New materials – like bio-based foams and vacuum insulation panels – can match or exceed traditional packaging performance, while significantly reducing environmental impact. But perhaps more transformative is the use of AI and real-time data to design and deploy packaging more precisely.
According to a 2024 article published in the International Journal of Life Cycle Assessment, lifecycle assessments (LCAs) are increasingly vital in evaluating packaging. In clinical packaging, reuse models reduce environmental impacts by 49% to 82%, compared with single-use equivalents, even when wash and reuse processes incur some emissions.
Meanwhile, innovative containers use highefficiency materials and modular design to reduce emissions while increasing payload efficiency. Recyclable active containers slash CO2 emissions thanks to better volumetric efficiency and lower return logistics burden.
Yet, as Rogerson emphasises, the biggest hurdle isn’t technological, but structural. “The deeper barrier is misalignment,” he explains. “If marketing is promising recyclability that the receiving market can’t deliver, or procurement is chasing unit price while QA insists on gold-standard thermal performance, the ‘materials problem’ will never be solved.”
Explaining further Rogerson shares, “Cost perception will remain skewed. Regulatory sign-off will stall. Without a shared definition of success and role-specific KPIs that work together, sustainable packaging is layered on top of existing systems rather than built into them – and bolt-ons tend to fail under operational pressure.”
Suitability redefined
But the biggest shift may come not from how packaging performs in transit, but what happens once it’s done. At the moment, most temperature-controlled packaging is designed for single use. Once it arrives, it’s binned, or at best, sent for recycling.
The result? An industry that generates high-value waste – often unrecoverable and unrefusable. Perhaps, this may even be a missed opportunity. After all, in other sectors we are increasingly seeing refill and reuse models that work – such as bringing back soap bottles to the store to refill. So why can’t we do that with pill bottles, or cold chain containers?
According to Rogerson, circularity in pharma is less about theory and more about execution: “The solutions that work are those designed for controlled environments, such as depot-to-site or central pharmacy return lanes. These allow for closed-loop reuse of validated passive shippers, embedded reverse logistics with pre-printed return labels and GS1 2D codes, and proven recovery pathways for insulation and PCMs. The mistake many companies make is bolting these practices on to existing systems without first aligning the players.”
Pharmaceutical packaging is tightly controlled, and for good reason. But there’s growing recognition that circular models – whether through reusable passive shippers or returnable packaging – could offer both environmental and commercial benefits. But according to Rogerson, the emphasis on coordination is critical: “Circularity succeeds when the business case is built on both compliance and cost performance, and when every function agrees on what ‘success’ means before launch. The alignment is the multiplier.”
Still, even the best ideas run into resistance. The safety-first mindset has served the industry well. But it also creates inertia, making it hard to test or adopt new models. And regulation isn’t entirely to blame. As Rogerson points out, global rules are not uniform in practice: “The EU’s Packaging & Packaging Waste Regulation is accelerating recyclability and designfor- recovery, while GS1’s Sunrise 2027 digital ID migration supports traceable, reusable assets. But in many markets, regulations are replicated without matching recovery or recycling infrastructure. Companies are left with compliance requirements that are technically unachievable locally.”
The road ahead
It’s difficult to find a balance in a world where the pharmaceutical industry is developing rapidly. The global temperature-controlled packaging solution market is expected to rise from $13.8bn in 2025, to $23.6bn by 2035, according to Future Markets Insight. With the market growing so rapidly, it’s understandable as to why sustainability hasn’t been at the forefront. But this needs to change.
What would help? Rogerson argues the answer isn’t softer rules, but clearer ones. “Pharma doesn’t need ‘softer’ regulations; it needs clearer, more aligned ones that reward both performance and sustainability. Equivalence pathways for packaging changes, explicitly reuse recognition in GDP, sectorspecific recyclability standards, circularity incentives and mandatory digital IDs for tertiary containers would make the biggest difference. But critically, regulators and industry must co-design these shifts with infrastructure realities in mind.”
In the end, sustainability doesn’t have to mean compromising on safety – it means expanding the definition of what suitability really looks like. Yes, cold chain packaging must protect products. But it should also be resource-efficient, non-toxic and fit within a circular economy model.
That’s no small ask, but most definitely not impossible either. The tools already exist, as do the materials. And with the pressure that is ever growing, all that is needed now is alignment across all aspects of the supply chain – from procurement, to regulation, design and logistics.
Or, as Rogerson neatly concludes: “When sustainability is treated as a parallel agenda instead of being integrated into the same performance and cost frameworks, every function solves for different outcomes – and nothing changes at scale.”
The growing impact of sustainable cold chain packaging
Environmental impact
The pharmaceutical industry generates approximately 300,000 tonnes of plastic waste annually, with about half originating from single-use packaging solutions. Source: Pharmaceutical Technology
Sustainability initiatives
The reusable cold chain packaging market is projected to more than double in size by 2034, driven by industry-wide adoption.
Source: Towards Packaging
Regulatory alignment
Good distribution practices (GDP) emphasise the importance of coordination, collaboration and continuous quality improvement to ensure patient safety and product quality.
Source: Quality Matters
